Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery
NCT07594509Not yet recruiting
- Sponsor
- Nanjing Medical University
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Vericiguat oral suspension (Formulation 4) in heart failure (HF) (2 arms), sponsored by Nanjing Medical University. Primary endpoints: Incidence of Early Postoperative Hemodynamic Deterioration or Clinically Significant Myocardial Injury at 7 days, Incidence of Major Adverse Cardiovascular Events at 6 months and 2 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07594509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594509.